


WHAT IS CLAIMED IS:

1. A compound of Formula (I), a stereoisomer or a mixture of stereoisomers, a pharmaceutically acceptable salt, or hydrate thereof:



Formula (I)

5 wherein:

R^1 is selected from H, or C_1 - C_6 alkyl, each of which is substituted with 0, 1, 2, or 3 R^6 ;

R^2 and R^3 are each independently selected from H, C_1 - C_3 alkyl, or C_1 - C_3 haloalkyl, each of which is substituted with 0, 1, 2, or 3 R^6 ;

each R^4 is independently selected from H, hydroxyl, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, or C_1 - C_3

10 haloalkyl, each of which is substituted with 0, 1, 2, or 3 R^6 , or two R^4 groups are taken together to form an oxo;

R^5 is selected from halogen, hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, C_1 - C_3 haloalkyl, $-N(R^7)_2$, and -CN, each of which is substituted with 0, 1, 2, or 3 R^6 ;

X^1 and X^2 are each independently selected from H, halogen, cyano, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, or
15 C_1 - C_6 haloalkyl each of which is substituted with 0, 1, 2, or 3 R^6 ;

X^3 and X^4 are each independently selected from H or halo;

L is a linker of 1 to 22 carbon atoms in length, wherein one or more carbon atoms are each optionally and independently replaced by a group selected from $C(O)$, O, NR^7 , S, C_2 -alkenyl, C_2 -alkynyl, cycloalkyl, aryl, heterocycle, and heteroaryl, each of which is substituted with 0, 1, 2, or 3 R^6 ;

20 each R^6 is independently selected from C_1 - C_6 alkyl, halo, cyano, and hydroxy,

each R^7 is independently selected from hydrogen, C_1 - C_6 alkyl, and acyl, each of which is substituted with 0, 1, 2, or 3 R^6 , or two R^7 groups are taken together to form a 3- to 6-membered heterocycle or heteroaryl.

25 2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is selected from H, or C_1 - C_6 alkyl, each of which is substituted with 0, 1, 2, or 3 R^6 .

3. The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein R^1 is selected from H or methyl, each of which is substituted with 0, 1, 2, or 3 R^6 .

4. The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein R^1 is selected from H or methyl.

30 5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R^1 is H.

6. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R^1 is methyl.
7. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R^2 and R^3 are each independently selected from H, C_1 - C_3 alkyl, or C_1 - C_3 haloalkyl, each of which is substituted with 0, 1, 2, or 3 R^6 .
8. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R^2 and R^3 are each independently selected from H and methyl, each of which is substituted with 0, 1, 2, or 3 R^6 .
9. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R^2 and R^3 are each independently selected from H and methyl.
10. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R^2 and R^3 are each H.
11. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R^2 and R^3 are each methyl.
12. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R^2 and R^3 are H and methyl, respectively.
13. The compound according to any one claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein each R^4 is independently selected from H, hydroxyl, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, or C_1 - C_3 haloalkyl, each of which is substituted with 0, 1, 2, or 3 R^6 , or two R^4 groups are taken together to form an oxo.
14. The compound according to any one claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein each R^4 is independently selected from H, hydroxyl, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, or C_1 - C_3 haloalkyl, or two R^4 groups are taken together to form an oxo.
15. The compound according to any one claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R^4 is H.
16. The compound according to any one claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein two R^4 groups are taken together to form an oxo.
17. The compound according to any one claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein R^5 is selected from halogen, hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, C_1 - C_3 haloalkyl, - $N(R^7)_2$, and -CN, each of which is substituted with 0, 1, 2, or 3 R^6 .
18. The compound according to any one claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein R^5 is selected from halogen, hydroxy, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, C_1 - C_3 haloalkyl, - $N(R^7)_2$, and -CN.
19. The compound according to any one claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein R^5 is selected from halogen.
20. The compound according to any one claims 1 to 19, or a pharmaceutically acceptable salt thereof, wherein R^5 is F.

21. The compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, wherein X^1 and X^2 are each independently selected from H, halogen, cyano, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, or C_1 - C_6 haloalkyl, each of which is substituted with 0, 1, 2, or 3 R^6 .
22. The compound according to any one of claims 1 to 21, or a pharmaceutically acceptable salt thereof, wherein X^1 and X^2 are each independently selected from H, halogen, cyano, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, or C_1 - C_6 haloalkyl.
23. The compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein X^1 and X^2 are each independently selected from H, F, CN, methyl, methoxy, trifluoromethyl.
24. The compound according to any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein X^1 and X^2 are each H.
25. The compound according to any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein X^1 and X^2 are each F.
26. The compound according to any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein X^1 and X^2 are H and methyl, respectively.
27. The compound according to any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein X^1 and X^2 are H and F, respectively.
28. The compound according to any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein X^1 and X^2 are H and methoxy, respectively.
29. The compound according to any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein X^1 and X^2 are F and methyl, respectively.
30. The compound according to any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein X^1 and X^2 are F and methoxy, respectively.
31. The compound according to any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein X^1 and X^2 are F and trifluoromethyl, respectively.
32. The compound according to any one of claims 1 to 31, or a pharmaceutically acceptable salt thereof, wherein X^3 and X^4 are each independently selected from H or halo.
33. The compound according to any one of claims 1 to 32, or a pharmaceutically acceptable salt thereof, wherein X^3 and X^4 are each independently selected from H or F.
34. The compound according to any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, wherein X^3 and X^4 are each H.
35. The compound according to any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, wherein X^3 and X^4 are each F.
36. The compound according to any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, wherein X^3 and X^4 are H and F, respectively.
37. The compound according to any one of claims 1 to 36, or pharmaceutically acceptable salt thereof, wherein L is a linker of 1 to 22 carbon atoms in length, wherein one or more carbon atoms are each optionally and independently replaced by a group selected from C(O), O, NR^7 , S, C_2 -alkenyl, C_2 -

alkynyl, cycloalkyl, aryl, heterocycle, and heteroaryl, each of which is independently substituted with 0, 1, 2, or 3 R⁶.

38. The compound according to any one of claims 1 to 37, or pharmaceutically acceptable salt thereof, wherein L is a linker of 1 to 20 carbon atoms in length, wherein one or more carbon atoms are each optionally and independently replaced by a group selected from C(O), O, NR⁷, S, C₂-alkenyl, C₂-alkynyl, cycloalkyl, aryl, heterocycle, and heteroaryl, each of which is independently substituted with 0, 1, 2, or 3 R⁶.

39. The compound according to any one of claims 1 to 38, or pharmaceutically acceptable salt thereof, wherein L is a linker of 1 to 18 carbon atoms in length, wherein one or more carbon atoms are each optionally and independently replaced by a group selected from C(O), O, NR⁷, S, C₂-alkenyl, C₂-alkynyl, cycloalkyl, aryl, heterocycle, and heteroaryl, each of which is independently substituted with 0, 1, 2, or 3 R⁶.

40. The compound according to any one of claims 1 to 39, or pharmaceutically acceptable salt thereof, wherein L is a linker of 1 to 16 carbon atoms in length, wherein one or more carbon atoms are each optionally and independently replaced by a group selected from C(O), O, NR⁷, S, C₂-alkenyl, C₂-alkynyl, cycloalkyl, aryl, heterocycle, and heteroaryl, each of which is independently substituted with 0, 1, 2, or 3 R⁶.

41. The compound according to any one of claims 1 to 40, or pharmaceutically acceptable salt thereof, wherein L is a linker of 1 to 14 carbon atoms in length, wherein one or more carbon atoms are each optionally and independently replaced by a group selected from C(O), O, NR⁷, S, C₂-alkenyl, C₂-alkynyl, cycloalkyl, aryl, heterocycle, and heteroaryl, each of which is independently substituted with 0, 1, 2, or 3 R⁶.

42. The compound according to any one of claims 1 to 41, or pharmaceutically acceptable salt thereof, wherein L is a linker of 1 to 12 carbon atoms in length, wherein one or more carbon atoms are each optionally and independently replaced by a group selected from C(O), O, NR⁷, S, C₂-alkenyl, C₂-alkynyl, cycloalkyl, aryl, heterocycle, and heteroaryl, each of which is independently substituted with 0, 1, 2, or 3 R⁶.

43. The compound according to any one of claims 1 to 42, or pharmaceutically acceptable salt thereof, wherein L is a linker of 1 to 10 carbon atoms in length, wherein one or more carbon atoms are each optionally and independently replaced by a group selected from C(O), O, NR⁷, S, C₂-alkenyl, C₂-alkynyl, cycloalkyl, aryl, heterocycle, and heteroaryl, each of which is independently substituted with 0, 1, 2, or 3 R⁶.

44. The compound according to any one of claims 1 to 43, or pharmaceutically acceptable salt thereof, wherein L is a linker of 1 to 8 carbon atoms in length, wherein one or more carbon atoms are each optionally and independently replaced by a group selected from O, NR⁷, S, C₂-alkenyl, C₂-alkynyl, cycloalkyl, aryl, heterocycle, and heteroaryl, each of which is independently substituted with 0, 1, 2, or 3 R⁶.

45. The compound according to any one of claims 1 to 44, or pharmaceutically acceptable salt thereof, wherein L is a linker of 1 to 8 carbon atoms in length, wherein one or more carbon atoms are each optionally and independently replaced by a group selected from C(O), O, NR⁷, S, C₂-alkenyl, C₂-alkynyl, cycloalkyl, aryl, heterocycle, and heteroaryl, each of which is independently substituted with 0, 1, 2, or 3 R⁶.

46. The compound according to any one of claims 1 to 45, or pharmaceutically acceptable salt thereof, wherein L is a linker of 1 to 6 carbon atoms in length, wherein one or more carbon atoms are each optionally and independently replaced by a group selected from C(O), O, NR⁷, S, C₂-alkenyl, C₂-alkynyl, cycloalkyl, aryl, heterocycle, and heteroaryl, each of which is independently substituted with 0, 1, 2, or 3 R⁶.


47. The compound according to any one of claims 1 to 46, or pharmaceutically acceptable salt thereof, wherein L is a linker of 1 to 4 carbon atoms in length, wherein one or more carbon atoms are each optionally and independently replaced by a group selected from C(O), O, NR⁷, S, C₂-alkenyl, C₂-alkynyl, cycloalkyl, aryl, heterocycle, and heteroaryl, each of which is independently substituted with 0, 1, 2, or 3 R⁶.


48. The compound according to any one of claims 1 to 47, or a pharmaceutically acceptable salt thereof, wherein L is a linker wherein two carbon atoms are each independently replaced by a heterocycle, each of which is independently substituted with 0, 1, 2, or 3 R⁶.


49. The compound according to any one of claims 1 to 47, or a pharmaceutically acceptable salt thereof, wherein L is a linker wherein one carbon atom is replaced by a heterocycle and one carbon atom is replaced by a cycloalkyl, each of which is independently substituted with 0, 1, 2, or 3 R⁶.

50. The compound according to any one of claims 1 to 47, or a pharmaceutically acceptable salt thereof, wherein L is a linker wherein more than one carbon atoms are each independently replaced by a group selected from C(O), O, NR⁴, S, C₂-alkenyl, C₂-alkynyl, cycloalkyl, aryl, heterocycle, and heteroaryl, each of which is substituted with 0, 1, 2, or 3 R⁶.


51. The compound according to any one of claims 1 to 47, or a pharmaceutically acceptable salt thereof, wherein L is a linker wherein more than one carbon atoms are each independently replaced by a group selected from C(O), O, and NR⁴, each of which is substituted with 0, 1, 2, or 3 R⁶.

52. The compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, wherein L is .

53. The compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, wherein L is .


54. The compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, wherein L is .

55. The compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt




thereof, wherein L is

56. The compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt




thereof, wherein L is

5 57. The compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt




thereof, wherein L is

58. The compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt




thereof, wherein L is

59. The compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt




10 thereof, wherein L is

60. The compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt




thereof, wherein L is

61. The compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt




thereof, wherein L is

15 62. The compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt



thereof, wherein L is

63. The compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt




thereof, wherein L is

64. The compound according to any one of claims 1 to 63, or a pharmaceutically acceptable salt

20 thereof, wherein the compound is stereoisomer.

65. The compound according to claim 64, wherein the compound is *cis*- isomer.

66. The compound according to claim 64, wherein the compound has a Formula (I)*:



Formula (I)*

67. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from:
- 5 *cis*-3-(5-(2-(2-(2-(4-(7-hydroxy-3-phenylchroman-4-yl)phenoxy)ethoxy)ethoxy)ethoxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
 - cis*-3-(5-(2-(2-((2-(4-(7-hydroxy-3-phenylchroman-4-yl)phenoxy)ethyl)(methyl)amino)ethoxy)ethoxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
 - cis*-3-(5-(2-(4-(2-(4-(7-hydroxy-3-phenylchroman-4-yl)phenoxy)ethyl)piperazin-1-yl)ethoxy)-1-
 - 10 oxoisindolin-2-yl)piperidine-2,6-dione;
 - cis*-5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)oxy)-N-(2-(4-(7-hydroxy-3-phenylchroman-4-yl)phenoxy)ethyl)-N-methylpentanamide;
 - cis*-3-(5-((5-(4-(4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperazin-1-yl)pentyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
 - 15 *cis*-3-(5-(6-(4-(4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperazin-1-yl)hex-1-yn-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
 - cis*-3-(4-(6-(4-(4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperazin-1-yl)hex-1-yn-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
 - cis*-2-(2,6-dioxopiperidin-3-yl)-5-((5-(4-(4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperazin-1-
 - 20 yl)pentyl)amino)isoindoline-1,3-dione;
 - cis*-3-(5-(3-(1-(2-(4-(7-hydroxy-3-phenylchroman-4-yl)phenoxy)ethyl)azetidin-3-yl)propoxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
 - cis*-3-(5-(4-(1-(2-(4-(7-hydroxy-3-phenylchroman-4-yl)phenoxy)ethyl)azetidin-3-yl)but-1-yn-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
 - 25 *cis*-3-(4-(4-(1-(2-(4-(7-hydroxy-3-phenylchroman-4-yl)phenoxy)ethyl)azetidin-3-yl)but-1-yn-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
 - cis*-2-(2,6-dioxopiperidin-3-yl)-5-(4-(5-(4-(7-hydroxy-3-phenylchroman-4-yl)phenoxy)pentyl)piperazin-1-yl)isoindoline-1,3-dione;
 - cis*-3-(5-(4-(5-(4-(7-hydroxy-3-phenylchroman-4-yl)phenoxy)pentyl)piperazin-1-yl)-1-oxoisindolin-2-
 - 30 yl)piperidine-2,6-dione;
 - cis*-3-(5-(4-(5-(2-fluoro-4-(3-(4-fluoro-3-(trifluoromethyl)phenyl)-7-hydroxychroman-4-yl)phenoxy)pentyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;

- cis*-3-(5-(4-(5-(2-fluoro-4-(3-(4-fluorophenyl)-7-hydroxychroman-4-yl)phenoxy)pentyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-3-(5-(4-(5-(2-fluoro-4-(3-(4-fluoro-3-methylphenyl)-7-hydroxychroman-4-yl)phenoxy)pentyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 5 *cis*-3-(5-(4-(5-(2-fluoro-4-(7-hydroxy-3-(*m*-tolyl)chroman-4-yl)phenoxy)pentyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-3-(5-(4-(5-(2-fluoro-4-(3-(4-fluoro-2-methylphenyl)-7-hydroxychroman-4-yl)phenoxy)pentyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-3-(5-(4-(5-(4-(3-(3,4-difluorophenyl)-7-hydroxychroman-4-yl)-2-fluorophenoxy)pentyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 10 *cis*-3-(5-(4-(5-(4-(3-(4-fluoro-3-(trifluoromethyl)phenyl)-7-hydroxychroman-4-yl)phenoxy)pentyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-3-(5-(4-(5-(4-(3-(4-fluoro-3-methoxyphenyl)-7-hydroxychroman-4-yl)phenoxy)pentyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 15 *cis*-3-(5-(4-(5-(4-(3-(4-fluoro-2-(trifluoromethyl)phenyl)-7-hydroxychroman-4-yl)phenoxy)pentyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-3-(5-(4-(5-(4-(3-(4-fluoro-3-methylphenyl)-7-hydroxychroman-4-yl)phenoxy)pentyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-3-(5-(4-(5-(4-(7-hydroxy-3-(*o*-tolyl)chroman-4-yl)phenoxy)pentyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 20 *cis*-3-(5-(4-(4-(4-(7-hydroxy-3-phenylchroman-4-yl)phenoxy)butyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-3-(5-(4-(5-(4-(7-hydroxy-2,2-dimethyl-3-phenylchroman-4-yl)phenoxy)pentyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 25 *cis*-3-(5-(4-(5-(4-(7-methoxy-3-phenylchroman-4-yl)phenoxy)pentyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 3-(5-(4-(5-(4-((2*R*,3*S*,4*R*)-7-hydroxy-2-methyl-3-phenylchroman-4-yl)phenoxy)pentyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 3-(5-(4-(5-(4-((2*S*,3*S*,4*R*)-7-hydroxy-2-methyl-3-phenylchroman-4-yl)phenoxy)pentyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 30 3-(5-(4-(5-(4-((2*R*,3*R*,4*S*)-7-hydroxy-2-methyl-3-phenylchroman-4-yl)phenoxy)pentyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 3-(5-(4-(5-(4-((2*S*,3*R*,4*S*)-7-hydroxy-2-methyl-3-phenylchroman-4-yl)phenoxy)pentyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 35 *cis*-(*S*)-3-(5-(4-((1-(4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- (*S*)-3-(5-(4-((1-(4-((3*S*,4*R*)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;

- (S)-3-(5-(4-((1-(4-((3R,4S)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
cis-3-(5-(4-((1-(4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 5 *cis*-2-(2,6-dioxopiperidin-3-yl)-5-(4-((1-(4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)isoindoline-1,3-dione;
cis-2-(2,6-dioxopiperidin-3-yl)-5-(4-(2-(1-(4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)ethyl)piperazin-1-yl)isoindoline-1,3-dione;
cis-2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-((1-(4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)isoindoline-1,3-dione;
- 10 *cis*-(S)-3-(6-fluoro-5-(4-((1-(4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
cis-(S)-3-(6-fluoro-5-(4-((1-(2-fluoro-4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 15 (S)-3-(6-fluoro-5-(4-((1-(2-fluoro-4-((3S,4R)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
(S)-3-(6-fluoro-5-(4-((1-(4-((3S,4R)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
(S)-3-(6-fluoro-5-(4-((1-(4-((3R,4S)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 20 *cis*-(S)-3-(5-(4-(2-(1-(4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)ethyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
(S)-3-(5-(4-((1-(2-fluoro-4-((3R,4S)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 25 (S)-3-(5-(4-((1-(2-fluoro-4-((3S,4R)-7-hydroxy-2,2-dimethyl-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
(S)-3-(5-(4-((1-(2-fluoro-4-((2R,3S,4R)-7-hydroxy-2-methyl-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
(S)-3-(5-(4-((1-(2-fluoro-4-((2S,3S,4R)-7-hydroxy-2-methyl-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 30 (S)-3-(5-(4-((1-(2-fluoro-4-((3S,4R)-7-methoxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
cis-(S)-3-(5-(4-((1-(2-fluoro-4-(3-(4-fluorophenyl)-7-hydroxychroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 35 *cis*-(S)-3-(5-(4-((1-(4-(3-(4-fluorophenyl)-7-hydroxychroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
cis-(S)-3-(5-(4-((1-(2-fluoro-4-(7-hydroxy-3-(*m*-tolyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;

- cis*-(S)-3-(5-(4-((1-(4-(7-hydroxy-3-(*m*-tolyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-(S)-3-(5-(4-((1-(2-fluoro-4-(7-hydroxy-3-(3-methoxyphenyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 5 (S)-3-(5-(4-((1-(2-fluoro-4-((3*S*,4*R*)-7-hydroxy-3-(3-methoxyphenyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-(S)-3-(5-(4-((1-(4-(7-hydroxy-3-(3-methoxyphenyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-3-(5-(4-((1-(4-(7-hydroxy-3-(3-methoxyphenyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 10 *cis*-(S)-3-(5-(4-((1-(2-fluoro-4-(7-hydroxy-3-(3-methoxyphenyl)-2,2-dimethylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-(S)-3-(5-(4-((1-(4-(7-hydroxy-3-(3-methoxyphenyl)-2,2-dimethylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 15 *cis*-(S)-3-(5-(4-((1-(2-fluoro-4-(3-(4-fluoro-3-methylphenyl)-7-hydroxychroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-(S)-3-(5-(4-((1-(2-fluoro-4-(3-(4-fluoro-3-methoxyphenyl)-7-hydroxychroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-(S)-3-(5-(4-((1-(4-(3-(4-fluoro-3-methylphenyl)-7-hydroxychroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 20 *cis*-(S)-3-(5-(4-((1-(4-(3-(4-fluoro-3-methoxyphenyl)-7-hydroxychroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-(S)-3-(5-(4-((1-(2-fluoro-4-(3-(4-fluoro-2-methylphenyl)-7-hydroxychroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 25 *cis*-(S)-3-(5-(4-((1-(4-(3-(4-fluoro-2-methylphenyl)-7-hydroxychroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-(S)-3-(5-(4-((1-(4-((2*R*)-7-hydroxy-3-(3-methoxyphenyl)-2-methylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-(S)-3-(5-(4-((1-(4-((2*S*)-7-hydroxy-3-(3-methoxyphenyl)-2-methylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 30 *cis*-3-(5-(3-(((1-(4-(7-hydroxy-3-(3-methoxyphenyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)(methyl)amino)prop-1-yn-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-3-(5-(3-(((1-(2-fluoro-4-(7-hydroxy-3-(3-methoxyphenyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)(methyl)amino)prop-1-yn-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 35 *cis*-3-(5-(3-(((1-(2-fluoro-4-(7-hydroxy-3-(*m*-tolyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)(methyl)amino)prop-1-yn-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-3-(5-(3-(((1-(4-(7-hydroxy-3-(*m*-tolyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)(methyl)amino)prop-1-yn-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;

- cis*-(S)-3-(6-fluoro-5-(4-((1-(2-fluoro-4-(7-hydroxy-3-(3-methoxyphenyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
cis-2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-((1-(2-fluoro-4-(7-hydroxy-3-(3-methoxyphenyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)isoindoline-1,3-dione;
- 5 *cis*-(S)-3-(6-fluoro-5-(4-((1-(4-(7-hydroxy-3-(3-methoxyphenyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
cis-2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-(4-((1-(4-(7-hydroxy-3-(3-methoxyphenyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)isoindoline-1,3-dione;
cis-(S)-3-(6-fluoro-5-(4-((1-(2-fluoro-4-(3-(4-fluoro-3-methylphenyl)-7-hydroxychroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 10 *cis*-(S)-3-(6-fluoro-5-(4-((1-(4-(3-(4-fluoro-3-methylphenyl)-7-hydroxychroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
cis-(S)-3-(6-fluoro-5-(4-((1-(2-fluoro-4-(7-hydroxy-3-(*m*-tolyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 15 *cis*-(S)-3-(6-fluoro-5-(4-((1-(4-(7-hydroxy-3-(*m*-tolyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
cis-(S)-3-(6-fluoro-5-(4-((1-(2-fluoro-4-(3-(4-fluoro-3-methoxyphenyl)-7-hydroxychroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
cis-(S)-3-(5-(4-((1-(2,6-difluoro-4-(7-hydroxy-3-(*m*-tolyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 20 *cis*-(S)-3-(5-(4-((1-(2-fluoro-4-(7-methoxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
cis-2-(2,6-dioxopiperidin-3-yl)-5-(4-((1-(2-fluoro-4-(7-methoxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)isoindoline-1,3-dione;
- 25 *cis*-(S)-3-(5-(4-((1-(4-(3-(3,4-difluorophenyl)-7-hydroxychroman-4-yl)-2-fluorophenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
cis-(S)-3-(5-(4-((1-(2-fluoro-4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
(S)-3-(5-(4-((1-(2-fluoro-4-((3*S*,4*R*)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 30 *cis*-2-(2,6-dioxopiperidin-3-yl)-5-(4-((1-(2-fluoro-4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)isoindoline-1,3-dione;
cis-(S)-3-(5-(4-((1-(2,6-difluoro-4-(7-hydroxy-3-(3-methoxyphenyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 35 *cis*-(S)-3-(5-(4-((1-(4-(7-hydroxy-3-(4-methoxyphenyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione; and
cis-(S)-3-(6-fluoro-5-(4-((1-(4-(7-hydroxy-3-(4-methoxyphenyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione.

68. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from:

- 5 *cis*-(S)-3-(5-(4-((1-(4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- (S)-3-(5-(4-((1-(4-((3S,4R)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- (S)-3-(5-(4-((1-(4-((3R,4S)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 10 *cis*-2-(2,6-dioxopiperidin-3-yl)-5-(4-((1-(4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)isoindoline-1,3-dione;
- (S)-3-(6-fluoro-5-(4-((1-(2-fluoro-4-((3S,4R)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- (S)-3-(6-fluoro-5-(4-((1-(4-((3S,4R)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 15 (S)-3-(5-(4-((1-(2-fluoro-4-((3R,4S)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-(S)-3-(5-(4-((1-(2-fluoro-4-(7-hydroxy-3-(*m*-tolyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 20 *cis*-(S)-3-(5-(4-((1-(2-fluoro-4-(3-(4-fluoro-3-methylphenyl)-7-hydroxychroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-(S)-3-(5-(4-((1-(4-(3-(3,4-difluorophenyl)-7-hydroxychroman-4-yl)-2-fluorophenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-(S)-3-(5-(4-((1-(2-fluoro-4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 25 (S)-3-(5-(4-((1-(2-fluoro-4-((3S,4R)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione; and
- cis*-2-(2,6-dioxopiperidin-3-yl)-5-(4-((1-(2-fluoro-4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)isoindoline-1,3-dione.

30

69. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from:

- (S)-3-(5-(4-((1-(4-((3S,4R)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 35 *cis*-2-(2,6-dioxopiperidin-3-yl)-5-(4-((1-(4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)isoindoline-1,3-dione;
- (S)-3-(6-fluoro-5-(4-((1-(2-fluoro-4-((3S,4R)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;

- (S)-3-(6-fluoro-5-(4-((1-(4-((3S,4R)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
cis-(S)-3-(5-(4-((1-(2-fluoro-4-(7-hydroxy-3-(*m*-tolyl)chroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 5 *cis*-(S)-3-(5-(4-((1-(2-fluoro-4-(3-(4-fluoro-3-methylphenyl)-7-hydroxychroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
cis-(S)-3-(5-(4-((1-(4-(3-(3,4-difluorophenyl)-7-hydroxychroman-4-yl)-2-fluorophenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- (S)-3-(5-(4-((1-(2-fluoro-4-((3S,4R)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione; and
- 10 *cis*-2-(2,6-dioxopiperidin-3-yl)-5-(4-((1-(2-fluoro-4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)isoindoline-1,3-dione.

70. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from:

- (S)-3-(5-(4-((1-(4-((3S,4R)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
cis-2-(2,6-dioxopiperidin-3-yl)-5-(4-((1-(4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)isoindoline-1,3-dione;
- 20 (S)-3-(6-fluoro-5-(4-((1-(2-fluoro-4-((3S,4R)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
(S)-3-(6-fluoro-5-(4-((1-(4-((3S,4R)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- cis*-(S)-3-(5-(4-((1-(4-(3-(3,4-difluorophenyl)-7-hydroxychroman-4-yl)-2-fluorophenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione;
- 25 (S)-3-(5-(4-((1-(2-fluoro-4-((3S,4R)-7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisindolin-2-yl)piperidine-2,6-dione; and
cis-2-(2,6-dioxopiperidin-3-yl)-5-(4-((1-(2-fluoro-4-(7-hydroxy-3-phenylchroman-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)isoindoline-1,3-dione.

- 30 71. A pharmaceutical composition comprising the compound according to any one of claims 1 to 70 and at least one additional component selected from pharmaceutically acceptable carriers, pharmaceutically acceptable vehicles, and pharmaceutically acceptable excipients.

72. The pharmaceutical composition according to claim 71, wherein the compound is present in a therapeutically effective amount.

- 35 73. A method of treating cancer in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to any one of claims 1 to 70 or of the pharmaceutical composition according to claim 66 or 67, wherein the cancer is selected from breast cancer, lung cancer, ovarian cancer, endometrial cancer, prostate cancer, and esophageal cancer.

74. The method according to claim 73, wherein the cancer is breast cancer.
75. The method according to claim 74, wherein the cancer is ovarian cancer.
76. The method according to any one of claims 73 to 75, wherein the cancer is positive for ER α .
77. The method according to any one of claims 74 to 76, wherein the subject has been previously
5 treated with an anti-cancer agent.
78. The method according to claim 77, wherein the anti-cancer agent is tamoxifen.
79. The method according to claim 77, wherein the anti-cancer agent is fulvestrant.
80. A use of the compound according to any one of claims 1 to 70 in a method of therapeutic
treatment, wherein said therapeutic treatment is selected from treatment of breast cancer, lung cancer,
10 ovarian cancer, endometrial cancer, prostate cancer, esophageal cancer, infertility, ovulatory dysfunction,
postmenopausal osteoporosis, estrogen-related gynecomastia, dyspareunia due to menopause,
retroperitoneal fibrosis, and idiopathic sclerosing mesenteritis.
81. A use of the compound according to any one of claims 1 to 70 in the preparation of a
medicament.
- 15 82. The use according to claim 81, wherein the medicament is for the treatment of breast cancer,
lung cancer, ovarian cancer, endometrial cancer, prostate cancer, esophageal cancer, infertility, ovulatory
dysfunction, postmenopausal osteoporosis, estrogen-related gynecomastia, dyspareunia due to
menopause, retroperitoneal fibrosis, and idiopathic sclerosing mesenteritis.
83. A method of inhibiting cell growth, comprising contacting a cell with the compound
20 according to any one of claims 1 to 70 or the pharmaceutical composition according to claim 71 or 72.
84. The method according to claim 83, wherein the cell is a cancer cell.
85. The method according to claim 83 or 84, wherein the cell expresses ER α .